Additional file 7: of Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâs disease (BLAZE)
- Stephen Salloway (5194271)
- Lee Honigberg (201340)
- William Cho (3004272)
- Michael Ward (146461)
- Michel Friesenhahn (5772140)
- Flavia Brunstein (5772143)
- Angelica Quartino (5772146)
- David Clayton (2150)
- Deborah Mortensen (4852741)
- Tobias Bittner (237241)
- Carole Ho (5772149)
- Christina Rabe (5772152)
- Stephen Schauer (2307406)
- Kristin Wildsmith (5772155)
- Reina Fuji (1845652)
- Shehnaaz Suliman (5772158)
- Eric Reiman (3703348)
- Kewei Chen (298512)
- Robert Paul (22962)
Publication date
September 2018
DOIAbstract
Figure S5. CDR-SB. Change from baseline (BL) of CDR-SB score in patients with mild-to-moderate AD (A and C) or mild AD (B and D) in the low-dose SC (A and B) and high-dose IV (C and D) cohorts. (PDF 112 kb
Add to ORKG